Nature Search

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

An analysis of 24,202 critical cases of COVID-19 identifies potentially druggable targets in inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).

Erola Pairo-Castineira
Konrad Rawlik
J. Kenneth Baillie
ResearchOpen Access17 May 2023
Nature

Volume: 617, P: 764-768
Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity

In this study, the authors identify a collaboration between the epigenetic regulators, EZH2 and DNA methyltransferase that contributes to prostate cancer lineage reprogramming.

Richa Singh
Varadha Balaji Venkadakrishnan
Himisha Beltran
ResearchOpen Access21 Feb 2026
Nature Communications

Volume: 17, P: 1-14
Mapping the human genetic architecture of COVID-19

A global network of researchers was formed to investigate the role of human genetics in SARS-CoV-2 infection and COVID-19 severity; this paper reports 13 genome-wide significant loci and potentially actionable mechanisms in response to infection.

Mari E. K. Niemi
Juha Karjalainen
Chloe Donohue
ResearchOpen Access08 Jul 2021
Nature

Volume: 600, P: 472-477
Whole-genome sequencing reveals host factors underlying critical COVID-19

Whole-genome sequencing, transcriptome-wide association and fine-mapping analyses in over 7,000 individuals with critical COVID-19 are used to identify 16 independent variants that are associated with severe illness in COVID-19.

Athanasios Kousathanas
Erola Pairo-Castineira
J. Kenneth Baillie
ResearchOpen Access07 Mar 2022
Nature

Volume: 607, P: 97-103
A second update on mapping the human genetic architecture of COVID-19

Masahiro Kanai
Shea J. Andrews
Matthew Solomonson
ResearchOpen Access06 Sept 2023
Nature

Volume: 621, P: E7-E26
Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Erola Pairo-Castineira
Konrad Rawlik
J. Kenneth Baillie
Amendments and CorrectionsOpen Access11 Jul 2023
Nature

Volume: 619, P: E61
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Sera from vaccinated individuals and some monoclonal antibodies show a modest reduction in neutralizing activity against the B.1.1.7 variant of SARS-CoV-2; but the E484K substitution leads to a considerable loss of neutralizing activity.

Dami A. Collier
Anna De Marco
Ravindra K. Gupta
Research11 Mar 2021
Nature

Volume: 593, P: 136-141
SARS-CoV-2 evolution during treatment of chronic infection

Chronic infection with SARS-CoV-2 leads to the emergence of viral variants that show reduced susceptibility to neutralizing antibodies in an immunosuppressed individual treated with convalescent plasma.

Steven A. Kemp
Dami A. Collier
Ravindra K. Gupta
Research05 Feb 2021
Nature

Volume: 592, P: 277-282
Targeting anti-androgen therapy resistance through epigenetic rewiring

Although resistance develops in response to androgen receptor-targeted therapy in advanced prostate cancer, the underlying mechanisms remain unclear. The protein ZMYND8 is now shown to bind FOXM1 and the SWI–SNF complex, promoting the onset of neuroendocrine prostate cancer, which can thus be abrogated through small-molecule ZMYND8 inhibition.

Kate E. Dunmore
David S. Rickman
News & Views18 Mar 2025
Nature Cancer

Volume: 6, P: 564-566
Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier
Anna De Marco
Ravindra K. Gupta
Amendments and Corrections21 Jul 2022
Nature

Volume: 608, P: E24
Author Correction: SARS-CoV-2 evolution during treatment of chronic infection

Steven A. Kemp
Dami A. Collier
Ravindra K. Gupta
Amendments and Corrections21 Jul 2022
Nature

Volume: 608, P: E23

Search

Filter By:

Search

Quick links